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Only a few studies in children have evaluated the efﬁcacy of prophylactic regimens using tacrolimus on acute
graft-versus-host disease (aGVHD). As a result, optimal tacrolimus levels in children after matched sibling
donor allogeneic hematopoietic cell transplantation (alloHCT) are not well deﬁned. We measured the asso-
ciation between subtherapeutic levels (<10 ng/mL) during weeks 1 to 4 after alloHCT and the cumulative
incidence of grades II to IV aGVHD in children. Additionally, we identiﬁed optimal lower cutoff levels for
tacrolimus. Sixty patients (median age, 8 years) received tacrolimus/mycophenolate mofetil between March
2003 and September 2012. Twenty-three had a malignant disease and 37 nonmalignant disorders. The stem
cell source included peripheral blood stem cells (n ¼ 12) and bone marrow or cord blood (n ¼ 48). Condi-
tioning regimen varied. Speciﬁcally, 38.3% received a myeloablative regimen, 36.7% receiving a reduced-
toxicity regimen, and 25% receiving a reduced-intensity regimen. Tacrolimus was initiated at .03 mg/kg/
day via continuous i.v. infusion or .12 mg/kg/day orally. The dose was adjusted to maintain daily steady state
concentrations within a range of 10 to 20 ng/mL. The overall incidence of grades II to IV aGVHD was 33.3%. On
multivariate analysis, a mean tacrolimus level < 10 ng/mL during week 3 (P ¼ .042; 95% conﬁdence interval,
1.051 to 14.28) was signiﬁcantly associated with increased incidence of grades II to IV aGVHD. Using weekly
receiver operator curves, the optimal lower cutoff for tacrolimus levels was 10 to 11.2 ng/mL. Further pro-
spective studies are warranted to study the incidence of aGVHD comparing the conventional tacrolimus levels
of 5 to 15 versus 10 to 15 ng/mL.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
In advancing the success of allogeneic hematopoietic
cell transplantation (alloHCT) in the treatment of malignant
and nonmalignant disorders, acute graft-versus-host disease
(aGVHD) remains a formidable challenge, contributing
signiﬁcantly to overall morbidity and mortality. The cumu-
lative incidence of aGVHD grades II to IV in pediatric matched
sibling donor (MSD) alloHCT has been reported as 27% andedgments on page 501.
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ty for Blood and Marrow Transplantation.28% to 33% for peripheral blood stem cell (PBSC) and bone
marrow (BM) transplantation, respectively [1,2]. Optimizing
prophylactic regimens for prevention of aGVHD is therefore
of major importance in improving survival after alloHCT.
In 2004, our institution reported a pilot study of 34 chil-
dren who underwent MSD or matched unrelated donor
alloHCT and received tacrolimus/mycophenolate mofetil
(Tacro/MMF) for aGVHD prophylaxis. In this study, the inci-
dence of grades II to IV aGVHD was 45.4% [3]. Over the last
decade we have continued to use a Tacro/MMF regimen but
have yet to evaluate its efﬁcacy on our larger sample or to
assess optimal tacrolimus levels.
Major toxicities of tacrolimus include hypomagnesemia,
nephrotoxicity, hypertension, and neurotoxicity, which
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administration [1]. In a study by Przepiorka et al. [4], serum
tacrolimus levels greater than 20 ng/mL were associated
with an increased risk of adverse effects. This study and
others in adults suggest a target range for whole blood
tacrolimus levels of 10 to 20 ng/mL [4,5].
Several adult studies have investigated the optimal whole
blood tacrolimus concentration in preventing aGVHD after
alloHCT, with varied results. In a study by Przepiorka et al.
[6], patients with tacrolimus levels <5 ng/mL showed a 1.7-
fold increased incidence of grades II to IV aGVHD and a
3.1-fold increased incidence of grades III to IV aGVHD. Sub-
sequently, in another large retrospective study, Ram et al. [7]
demonstrated that tacrolimus levels >10.5 ng/mL after
nonmyeloablative conditioning were associated with a
decreased incidence of grades III to IV aGVHD. This was fol-
lowed by a study from Mori et al. [8] reporting a signiﬁcant
association between aGVHD incidence and mean tacrolimus
concentrations <15 ng/mL. Very little sense can be made
from these widely varying results. This leaves no true stan-
dard for the optimal target range for tacrolimus.
Even fewer published reports have addressed target levels
of tacrolimus in children after alloHCT. Applying the results of
existing adult studies to the pediatric population is not ideal.
Children have demonstrated increased metabolic clearance of
tacrolimus when compared with adults [9,10]. Of note, a small
study of patients <18 years old demonstrated a signiﬁcant
correlation in which mean whole blood tacrolimus levels
<7 ng/mL were associated with grades II to IV aGVHD [11].
The present study is a retrospective analysis evaluating
the efﬁcacy of prophylactic Tacro/MMF and the competing
risk factors that may impact the occurrence of grades II to IV
aGVHD in pediatric patients undergoing MSD alloHCT. We
also questioned the currently accepted target range of 10 to
20 ng/mL for tacrolimus by measuring the association be-
tweenwhole blood levels<10 ng/mL during the ﬁrst 4 weeks
after alloHCT and the cumulative incidence of grades II to IV
aGVHD in children. Additionally, we attempted to identify
lower values for whole blood tacrolimus range at various
time points after alloHCT that may be more appropriate
targets for prophylactic dosing. We hypothesize that sub-
therapeutic tacrolimus levels were associated with a higher
incidence of aGVHD.
METHODS
Subjects
The study population comprised consecutive pediatric patients between
March 2003 and September 2012 who underwent 6/6 HLA-matched MSD
alloHCT and received Tacro/MMF for aGVHD prophylaxis at the New York-
Presbyterian Morgan Stanley Children’s Hospital. Indications for alloHCT
were malignant disorders (n ¼ 23) and nonmalignant disorders (n ¼ 37).
Stem cell sources included BM (n ¼ 43), cord blood (CB; n ¼ 5), and PBSC
(n ¼ 12). Patients were excluded if they underwent ex vivo T cell depletion
before alloHCT. This retrospective study was approved by the Institutional
Review Board of Columbia University Medical Center.
HLA Typing
HLA typing was performed by intermediate resolution for HLA-A and -B
and by high-resolution DNA typing for HLA-DRB1. All subjects had a 6/6 HLA
MSD.
Conditioning Regimens
Preparative regimens included myeloablative conditioning (MAC),
reduced-intensity conditioning (RIC), and reduced-toxicity conditioning
(RTC). Of our study population, 38.3% received MAC, 25% received RIC, and
36.7% received RTC.
MAC regimens included total body irradiation þ cyclophosphamide
(120mg/kg) thiotepa (10mg/kg) or total body irradiationþmelphalan (90
to 135 mg/m2) and 2 alkylators, i.v. busulfan (12.8 to 16 mg/kg) þ cyclophosphamide (120 to 200 mg/kg) or i.v. busulfan (12.8 to 16 mg/
kg) þ melphalan (135 mg/m2). RTC regimens included patients who
received ﬂudarabine (150 to 180 mg/m2) and i.v. busulfan (12.8 to 16 mg/
kg)  alemtuzumab (54 mg/m2) or ﬂudarabine (150 mg/m2) and cyclo-
phosphamide (200 mg/kg)  rabbit antithymocyte globulin (r-ATG; 8 mg/
kg). RIC regimens included patients who received ﬂudarabine (150 mg/m2)
and i.v. busulfan (6.4 to 8 mg/kg)  r-ATG (8 mg/kg) or ﬂudarabine (150 mg/
m2) and cyclophosphamide (60 mg/kg)  r-ATG (8 mg/kg).
Twenty patients received alemtuzumab (33.3%) and 14 patients received
r-ATG (23.3%). Patients at high risk for graft failure such as hemoglobinop-
athies received alemtuzumab, and patients with severe aplastic anemia
received ATG.GVHD Prophylaxis
All subjects received Tacro/MMF for aGVHD prophylaxis. Tacrolimuswas
initiated on day e9 (RIC and RTC) and day e1 (MAC) before alloHCT at
.03 mg/kg/day via i.v. infusion or .12 mg/kg/day orally divided every 8 to
12 hours. Tacrolimus was started early in patients receiving RIC to suppress
the host immune system to decrease the risk of rejection. Tacrolimus dosing
was adjusted to maintain whole blood steady state (i.v.) or trough (p.o.)
levels between 10 and 20 ng/mL (whole blood enzyme-linked immuno-
sorbent assay). Daily tacrolimus levels were drawn. Once patients were able
to tolerate oral medications, they were transitioned to oral tacrolimus ac-
cording to the currently accepted conversion factor of 4:1 (p.o./i.v. dose). For
patients with malignant disorders, tacrolimus was tapered after day þ60 if
patients had grade  II aGVHD. For patients with nonmalignant disorders, a
tacrolimus taper started on day þ180 [3].
MMFwas initiated on dayþ1 at 900mg/m2 i.v. or orally on a 3 to 4 times
a day dosing schedule. Patients were converted to an equivalent oral MMF
dose once tolerating oral medications. Mycophenolic acid trough concen-
trations were obtained weekly for a minimum of the ﬁrst 4 weeks. Serum
levels of mycophenolic acid were determined by using reverse-phase HPLC.
Levels less than .5 mg/mL were undetectable by the current assay and were
designated as 0 in the analysis. In patients with malignant disorders, MMF
was discontinued or tapered after dayþ30 if patients had grade II aGVHD.
For patients with nonmalignant disorders, MMF was stopped at day þ180
[3].Supportive Care
Patients received standard supportive care measures as described in
Osunkwo et al. [3]. Herpes simplex virus prophylaxis consisted of i.v.
acyclovir (250 mg/m2) every 8 hours from day 5 until engraftment and
mucositis  grade II. Initially, fungal prophylaxis consisted of i.v. liposomal
amphotericin B (3 mg/kg/day) starting on day 0 through day þ100, as pre-
viously described [12]. Since 2007, however, most patients have received i.v.
liposomal amphotericin B (1.5 mg/kg) until dayþ45 and then micafungin (1
to 1.5 mg/kg) until day þ100 for fungal infection prophylaxis [13]. Cyto-
megalovirus (CMV) prophylaxis was administered as previously described
[14]. Brieﬂy, patients at risk of acquiring CMV infection (CMVþ donor and/or
recipient), after achieving an absolute neutrophil count >.75  109/L post-
alloHCT, received prophylaxis with foscarnet (90 mg/kg per dose) every
other day, alternating with ganciclovir (5 mg/kg per dose) every other day
until day þ100. Since 2010 due to foscarnet shortages, patients received
daily ganciclovir.Data Collection
Patient demographic informationwas obtained from the medical record
and included age, gender, ethnicity, nonmalignant/malignant diseases, HLA
matching, donor source, conditioning regimen, and CMV status. Information
was also obtained on administration of r-ATG or alemtuzumab and con-
current medications that may affect tacrolimus levels (azoles and eichino-
candin antifungal medications, metronidazole, and phenytoin).
All tacrolimus and MMF levels through day þ100 were collected, as
were levels of creatinine and bilirubin on days 0, 7, 14, 21, and 28. aGVHD
was diagnosed and graded according to established criteria [15]. Mean
whole blood tacrolimus concentrations were calculated for each patient
corresponding to days 1 to 7, 8 to 14, 15 to 21, 22 to 28, and 1 to 28, and the
number of days during which each patient had subtherapeutic tacrolimus
levels (<10 ng/mL) were counted. MMF levels during weeks 1 to 4 post-
transplant were collected, and mean MMF levels during the ﬁrst month
post-alloHCT were calculated.
Renal injury was deﬁned as having a serum creatinine during weeks 1 to
4 more than twice the baseline level measured at day 0 [16]. Liver toxicity
was deﬁned as any total bilirubin level during weeks 1 to 4 greater than 1.5
times the upper limit of normal (>1.95 mg/dL) [17].
Table 1
Characteristics of Children Receiving HLA MSD AlloHCT
Characteristic n %
Gender
Male 43 71.7
Female 17 28.3
Ethnicity
White 17 28.3
Black 11 18.3
Hispanic 20 33.3
Other 12 20.0
Age (range, .42-22)
<12 yr 36 60.0
12 yr 24 40.0
Diagnosis
Malignant 23 38.3
ALL 6 10.0
AML/MDS 13 21.7
Lymphoma 3 5.0
Other 1 1.7
Nonmalignant 37 61.7
Sickle cell disease 18 30.0
Thalassemia 5 8.3
Severe aplastic anemia 8 1.3
Others 6 10.0
Graft type
BM/CB 48 80.0
PBSC 12 20.0
Conditioning regimen
MAC 23 38.3
RIC 15 25.0
RTC 22 36.7
Immunotherapy
Alemtuzumab 20 33.3
r-ATG 14 23.3
None 26 43.3
Tacrolimus started i.v. 41 68.3
Tacrolimus started p.o. 19 31.7
ALL indicates acute lymphoblastic leukemia; MDS, myelodysplastic
syndrome.
Table 2
Incidence of Grades II to IV aGVHD among Children Receiving HLA MSD
AlloHCT
Number of Patients
with aGVHD
Percentage of Patients
with aGVHD
Grades II-IV aGVHD 20/60 33.3
Grades III-IV aGVHD 8/60 13.3
Grades II-IV Gut aGVHD 19/60 31.7
In vivo T cell depletion
Alemtuzumab (n ¼ 20) 5/20 25.0
r-ATG (n ¼ 14) 3/14 21.4
No serotherapy (n ¼ 26) 12/26 46.2
Graft source
BMþCB 13/48 27.1
PBSC 7/12 58.3
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Patient characteristics were summarized with descriptive statistics us-
ing percentages for categorical variables and mean  SE and range for
continuous variables. Cumulative incidence estimates of grades II to IV and
III to IV aGVHD and their associated 95% conﬁdence intervals (CIs) were
evaluated, treating death or recurrent malignancy without aGVHD within
the 100 days post-alloHCT as competing events. The logistic regression
analysis was used to assess risk factors for grades II to IV aGVHD and sub-
therapeutic tacrolimus levels (<10 ng/mL). Factors with a probable associ-
ation with grades II to IV aGVHD (P < .2) in univariate analyses were
included in multivariate analyses using the logistic regression models.
Receiver operator characteristic (ROC) curves were created using whole
blood tacrolimus levels and incidence of grades II to IV aGVHD for days 1 to
28 post-alloHCT to determine lower cutoff values for tacrolimus levels
with balanced speciﬁcity and sensitivity. Kaplan-Meier estimates and the
log-rank test were used to examine overall survival (OS). SAS 9.3 (SAS
Institute Inc., Cary, NC) and R program using R-package cmprsk (http://
cran.r-project.org/) were used.
Transplant-related mortality (TRM) was deﬁned as death due to any
transplant-related cause other than disease relapse. Event-free survival
(EFS) for patients with malignant disease was deﬁned as relapse/persistence
of the disease and death due to any cause other than disease relapse. EFS for
nonmalignant diseases was deﬁned as persistence of the disease, graft
failure, and death due to any cause. OS was deﬁned as patients who were
alive with or without their original disease.
Neutrophil engraftment was deﬁned as an absolute neutrophil count
>.5109/L on the ﬁrst of 3 consecutive days. Primary graft failure (PGF) was
deﬁned as failure to achieve a donor-derived absolute neutrophil count
>.5  109/L by day þ42 and/or 50% whole blood donor chimerism by
day þ60 in all except immune deﬁciency patients. In patients with T cell or
combined immune deﬁciency, PGF was deﬁned as 50% T cell (CD3) donor
chimerism by day þ180. Patients who received a second stem cell infusion
before day þ42 for impending graft failures were also considered to have
PGF. Secondary graft failure was deﬁned as second stem cell infusion for
dropping chimerism after achieving primary engraftment.
RESULTS
Study Population
FromMarch 2003 to September 2012, 60 patients fulﬁlled
study inclusion criteria. Patient characteristics are listed in
Table 1. The median age of our patients was 8 years (range,
.42 to 21), and the median time to follow up was 5 years
(range, .18 to 10.8).
Hematopoietic Recovery
The median time for neutrophil engraftment was 14 days
(range, 7 to 47). Incidence of neutrophil engraftment by
30 days was 95%. The incidence of primary and secondary
graft failure was 0%.
Incidence of GVHD
During the ﬁrst 100 days after alloHCT, the incidence of
grades II to IV aGVHD was 33.3% and the incidence of grades
III to IV aGVHDwas 13.3%. Of the total study population, most
patients (31.7%) developed gut GVHD compared with 8.3% of
patients who developed non-gut GVHD. Patients receiving
no serotherapy (neither alemtuzumab nor r-ATG) had a
46.2% incidence of grades II to IV aGVHD compared with 25%
of patients receiving alemtuzumab and 21.4% of patients
receiving r-ATG before alloHCT (Table 2). The probability of
developing grades II to IV aGVHD was higher in patients
receiving PBSC (58.3%) than patients receiving BM/CB
alloHCT (27.1%; P ¼ .08) by Fisher’s exact test.
Univariate Analysis of Risk Factors Associated with
Grades II to IV aGVHD
Potential risk factors associated with grades II to IV
aGVHD in patients undergoing MSD alloHCT were analyzed
(Table 3). On univariate analysis, the only risk factors
signiﬁcantly associated with grades II to IV aGVHD were
PBSC graft source compared with BM/CB (P ¼ .048; 95% CI,1.015 to 14.0) and mean tacrolimus level < 10 ng/mL during
week 3 after alloHCT compared with mean levels 10 ng/mL
(P ¼ .042; 95% CI, 1.051 to 14.28) (Figure 1).
Factors not associated with grades II to IV aGVHD
included having more than the median number of subther-
apeutic days (tacrolimus <10 ng/mL, median of 11 days;
P ¼ .711) and having undetectable MMF levels (<.5 mg/mL)
during weeks 1 to 4 post-alloHCT (P ¼ .196). We further
analyzed the data and found that MMF levels of .5, 1, or
2.0 mg/mL during weeks 1 to 4 post-alloHCT were not asso-
ciated with the decrease in the incidence of aGVHD.
Various other risk factors are described in Table 3, and
those with P < .2, such as absence of serotherapy (P ¼ .069)
and malignant underlying disease (P ¼ .064), were included
Table 3
Univariate Analysis of Risk Factors Associated with Grades II to IV aGVHD in
Children Receiving MSD AlloHCT
Variables Odds
Ratio
95% CI P
Age, yr .961 .872-1.058 .414
Age
<12 yr 1
12 yr .524 .167-1.640 .267
Male 1
Female .778 .230-2.627 .686
Graft type
BM/CB 1
PBSC 3.769 1.015-14.0 .048
In vivo T cell depletion
Yes 1
No 2.786 .922-8.416 .069
Disease type
Nonmalignant 1
Malignant 2.852 .939-8.658 .064
Conditioning regimen
RIC/RTC 1
MAC 2.077 .693-6.228 .192
Tacrolimus started i.v. 1
Tacrolimus started p.o. .890 .278-2.848 .845
Mean tacrolimus level week 1
10 ng/mL 1
<10 ng/mL 1.000 .310-3.226 1.0
Mean tacrolimus level week 2
10 ng/mL 1
<10 ng/mL .619 .186-2.061 .435
Mean tacrolimus level week 3
10 ng/mL 1
<10 ng/mL 3.875 1.051-14.28 .042
Mean tacrolimus level weeks 1-4
10 ng/mL 1
<10 ng/mL 2.200 .344-14.08 .405
Tacrolimus subtherapeutic
days weeks 1-4
 Median (11 d) 1
> Median (11 d) 1.227 .415-3.630 .711
Table 4
Multivariate Analysis of Risk Factors Associated with Grades II to IV aGVHD
in Children Receiving MSD AlloHCT
Variables Odds Ratio 95% CI P
Graft type
BM/CB 1
PBSC 3.530 .299-41.69 .317
Disease type
Nonmalignant 1
Malignant .887 .112-7.025 .909
In vivo T cell depletion
Yes 1
No 1.159 .163-8.259 .883
Conditioning regimen
RIC/RTC 1
MAC 1.241 .268-5.740 .782
Mean tacrolimus level week 3
10 ng/mL 1
<10 ng/mL 4.247 1.044-17.29 .043
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mean tacrolimus levels < 10 ng/mL during week 3 was the
only signiﬁcant independent risk factor associated with
grades II to IV aGVHD (P ¼ .043; 95% CI, 1.044 to 17.29)
(Table 4). Among the 60 patients, 7 patients experiencedFigure 1. Weekly ROC curve to determine optimal whole blood tacrolimus
levels with balanced sensitivity and speciﬁcity for weeks 1 to 4 post-alloHCT.aGVHD in the ﬁrst 2 weeks and were excluded in the week 3
analysis. During week 3, among the 53 patients, 15 patients
had average tacrolimus levels <10 and 38 patients had
average tacrolimus levels  10, and the incidence of aGVHD
in these 2 groups was 46.7% (7/15) versus 18.4% (7/38),
respectively.Determination of Target Lower Cutoff for Whole Blood
Tacrolimus Levels
Using whole blood tacrolimus levels measured daily
during the ﬁrst 4 weeks post-alloHCT, ROC curves were
created to identify a lower cutoff value for whole blood
tacrolimus levels below which prophylaxis of grades II to IV
aGVHD was impaired. The median number of tacrolimus
levels performed during the ﬁrst 28 days after alloHCT was
27 (range, 17 to 28). For each of the ﬁrst 4 weeks post-
alloHCT, a cutoff tacrolimus level was identiﬁed at which
there was optimal sensitivity and speciﬁcity for predicting
grades II to IV aGVHD (Table 5, Figure 1). These lower cutoff
levels for whole blood tacrolimus levels varied over time
between 10 and 11.2 ng/mL, but the overall cutoff for weeks 1
to 4 was 11 ng/mL. Figure 2 shows the overall trend of cutoff
levels during weeks 1 to 4, with the maximum level (11.2 ng/
mL) required at week 3.Renal Injury
Patients were considered to have renal injury if they had
doubling of serum creatinine compared with day 0. In our
study, the incidence of renal injury on days 7, 14, 21, and 28
was 8%, 20%, 27%, and 35%, respectively. The incidence of
renal injury was higher in patients with tacrolimus levels
10 compared with <10 ng/mL (week 1: 5.6% versus 9.5%;
week 2: 10.5% versus 22%; week 3: 16.7% versus 31%; week 4:
33% versus 36%). However, it did not reach statistical
signiﬁcance.Table 5
Weekly ROC Curve to Determine Optimal Whole Blood Tacrolimus Levels
with Balanced Sensitivity and Speciﬁcity for Weeks 1 to 4 Post-AlloHCT
Cutoff Sensitivity Speciﬁcity P Index
7 d 10.0 .47529 .54125 .34794 .25725
14 d 10.7 .52030 .50331 .34251 .26188
21 d 11.2 .49866 .52143 .27568 .26002
28 d 11.0 .528 .53266 .17260 .28125
Figure 2. Estimated OS. (A) Overall cumulative survival for all patients. (B) Kaplan-Meier curve showing OS of patients with malignant disease versus patients with
nonmalignant disease. (C) Probability of TRM versus death from relapse in patients with malignant disease. (D) Kaplan-Meier curve showing OS for patients receiving
PBSC versus BM and CB allografts.
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Median time to follow-up in this studywas 5 years (range,
.18 to 10.8). OS and EFS for all patients was 81% (SE, 5.2%)
(Figure 2A) and for patients with malignant and nonmalig-
nant diseases was 59% (SE, 10.7%) versus 95% (SE, 3.7%;
P < .001), respectively (Figure 2B). Death from relapse in
patients with malignant disease was 28.1% (SE, 10.2%), and
the incidence of TRM was 13.0% (SE, 7.2%) (Figure 2C). Five
patients suffered TRM within the ﬁrst year after alloHCT. Of
these, 2 patients had nonmalignant and 3 patients malignant
diseases. One patient each died because of candida menin-
goencephalitis, septic shock, thrombotic microangiopathy,
pulmonary ﬁbrosis, and adenovirus pneumonia.
The probability of mortality for patients undergoing PBSC
alloHCT was 50% (SE, 14.4%). This was signiﬁcantly higher in
comparison with patients undergoing BM/CB alloHCT with a
probability of mortality of 11.3% (SE, 4.8%; P < .001) by
Kaplan-Meier product limit estimators (Figure 2D). Because
all patients who received PBSC hadmalignant disease, the OS
comparing BM/CB versus PBSC alloHCT in patients with
malignant disease was 68.2% versus 50% (SE, 14.4%; P ¼ .184),
respectively. In the PBSC alloHCT cohort, 33.3% (SE, 14.5%)
had disease relapse and 16.7% (SE, 11.4%) had TRM (P ¼ .367).
DISCUSSION
To our knowledge, this is the largest retrospective study
in children analyzing the association between mean wholeblood tacrolimus levels and the incidence of aGVHD after
MSD alloHCT. One of the primary objectives of our study was
to evaluate the efﬁcacy of Tacro/MMF for aGVHD prophylaxis.
The results of this study demonstrate that in pediatric pa-
tients who underwent MSD alloHCT and received Tacro/
MMF, the incidence of grades II to IV aGVHD overall was
consistent with incidences reported in previous studies using
alternative prophylactic regimens. The incidence for grades II
to IV aGVHD in our study was 33.3%. This was similar to the
incidence of 33% reported by Yanik et al. [1] using Tacro/
methotrexate for aGVHD prophylaxis in MSD alloHCT and of
27% to 28% reported by Eapen et al. [2] using a variety of
aGVHD prophylaxis regimens including cyclosporine/meth-
otrexate and cyclosporine/other.
On further analysis, we noticed that the incidence of
aGVHD in patients receiving MSD PBSCs in our study (58.3%)
was higher than the incidence of aGVHD (28%) in previously
published literature by the Center for International Blood
and Marrow Transplant Research [2]. Interestingly, in a
recent prospective phase II adult study of predominantly
PBSC transplants (98% of patients), Al-Kadhimi et al. [18]
demonstrated that Tacro/MMF may provide suboptimal
protection against severe aGVHD, as they reported a cumu-
lative incidence of 47.4% for grades II to IV and 22.3% for
grades III to IV aGVHD in patients undergoing MSD alloHCT.
Additionally, another phase II randomized prospective
study in adults by Perkins et al. [19] reported that although
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patients receiving Tacro/MMF and Tacro/methotrexate
aGVHD prophylaxis regimen, patients who received Tacro/
MMF had worse severity of aGVHD overall. For this reason,
they cautioned using this prophylactic regimen, particularly
in patients at high risk for aGVHD such as those undergoing
PBSC alloHCT. Based on these data as well as the results of
our study, Tacro/MMF may not be sufﬁcient prophylaxis for
prevention of clinically signiﬁcant aGVHD in patients
receiving MSD PBSC alloHCT. As a result of high incidence of
aGVHD and no clear advantage in OS and relapse in patients
with malignant diseases after PBSC alloHCT, at our center we
reserve the practice of using PBSC allografts for MSD alloHCT
only if the donor is not eligible for BM harvest.
In our multivariate analysis, the only independent risk
factor associated with the occurrence of aGVHD was mean
tacrolimus levels < 10 during week 3 (P ¼ .043). This rela-
tionship is consistent with the results of the study by Mori
et al. [8] in which they demonstrated that lower mean
tacrolimus concentrations in the third week were signiﬁ-
cantly associated with grades II to IV aGVHD. Interestingly,
the largest retrospective study by Ram et al. [7] demon-
strated a signiﬁcant association between lower week 2
tacrolimus levels and cumulative incidence of grades III to IV
aGVHD in patients receiving non-MAC. We suspect the
reason this association was observed at these speciﬁc time
points after alloHCT is that lower tacrolimus levels early after
alloHCT may result in inadequate donor T cell suppression,
potentially leading to occurrence of aGVHD. Based on these
results, maintaining tacrolimus levels at 10 to 15 ng/mL
during ﬁrst 3 weeks post-alloHCT may decrease the inci-
dence of aGVHD. However, this ﬁnding should be conﬁrmed
prospectively.
To apply these observations to clinical practice in a spe-
ciﬁc and useful way, our study derived optimal lower cutoff
levels for tacrolimus, based onweekly ROC curves during the
initial 4 weeks post-alloHCT. The tacrolimus level each week
with the greatest sensitivity and speciﬁcity for predicting
aGVHDwas relatively stable over time and ranged from 10 to
11.2 ng/mL, with the highest cutoff calculated for week 3. The
only other pediatric group to use ROC curves to analyze
tacrolimus dosing was Watanabe et al. [11], who identiﬁed
7 ng/mL as the optimal lower cutoff level. Our results may
suggest a higher level than they did because their initial
target rangewas 5 to 15 ng/mL, whereas our target rangewas
10 to 20 ng/mL. It may be beneﬁcial to maintain levels be-
tween 10 and 15 ng/mL after alloHCT, with special attention
to maintaining levels >10 ng/mL during the ﬁrst 3 weeks.
Maintaining tacrolimus levels in this range (10 to 15 ng/ml)
rather than as high as 10 to 20 ng/mL may have potential
advantages such as reduced renal toxicity. In our study we
noticed a progressive increase in the incidence of renal
injury, which in part could be due to maintaining tacrolimus
levels between 10 and 20 ng/mL. The other beneﬁt of
maintaining tacrolimus levels between 10 and 15 ng/mL is
that it might hasten immune reconstitution, which may
potentially reduce the risk of relapse in patients with ma-
lignant diseases and viral infections post-alloHCT. However,
further prospective studies are warranted to study the inci-
dence of aGVHD and immune reconstitution comparing the
conventional tacrolimus level range of 5 to 15 versus 10 to
15 ng/mL [1].
In patients receiving Tacro/MMF aGVHD prophylaxis in
our study, the 5-year OS and EFS rates for patients with
malignant diseases and nonmalignant diseases was 59% and95%, respectively. We also found that in our cohort of pa-
tients with malignant disease, death from relapse (28%) was
higher than TRM (13%). The OS of patients receiving aGVHD
prophylaxis with Tacro/MMF and MSD alloHCT for nonma-
lignant disease was excellent. However, because of hetero-
geneous diagnosis and different intensities of conditioning
regimens, comparison of OS with other studies is
challenging.
Patients receiving immunotherapy (alemtuzumab or r-
ATG) had an approximately 50% lower incidence of aGVHD.
Immunotherapy was used exclusively in patients with
nonmalignant disorders (hemoglobinopathies and severe
aplastic anemia). Immunotherapy utilization was not only
associated with a decreased incidence of aGVHD but also was
associated with excellent OS and EFS. This ﬁnding should be
conﬁrmed prospectively.
In conclusion, although there is still a signiﬁcant inci-
dence of grades II to IV aGVHD in patients receiving Tacro/
MMF for prophylaxis after MSD alloHCT, our incidence was
consistent with other pediatric studies using a variety of
other prophylactic regimens. However, in our study, Tacro/
MMF prophylaxis regimens were associated with a higher
incidence of grades II to IV aGVHD and increasedmortality in
patients receiving PBSC alloHCT, which has since changed
our clinical practice. There still remains great uncertainty in
identifying an optimal target range for whole blood tacroli-
mus levels after MSD alloHCT in children. Our results suggest
that whole blood tacrolimus levels should be kept>10 ng/mL
at least through the third week post-transplant, and there is
utility in developing a target range, such as 10 to 15 ng/mL,
for the 4-week post-transplant course based on ROC curves.
Future prospective clinical trials are needed to investigate
optimal target levels (5 to 15 versus 10 to 15 ng/mL) as well
as to evaluate the use of Tacro/MMF in clinical practice
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